title: Smooth muscle tumors of soft tissue and non-uterine viscera: biology and prognosis.
abstract: Smooth muscle tumors are here considered an essentially dichotomous group composed of benign leiomyomas and malignant leiomyosarcomas. Soft tissue smooth muscle tumors with both atypia and mitotic activity are generally diagnosed leiomyosarcomas acknowledging potential for metastasis. However, lesions exist that cannot be comfortably placed in either category, and in such cases the designation 'smooth muscle tumor of uncertain biologic potential' is appropriate. The use of this category is often necessary with limited sampling, such as needle core biopsies. Benign smooth muscle tumors include smooth muscle hamartoma and angioleiomyoma. A specific category of leiomyomas are estrogen-receptor positive ones in women. These are similar to uterine leiomyomas and can occur anywhere in the abdomen and abdominal wall. Leiomyosarcomas can occur at any site, although are more frequent in the retroperitoneum and proximal extremities. They are recognized by likeness to smooth muscle cells but can undergo pleomorphic evolution ('dedifferentiation'). Presence of smooth muscle actin is nearly uniform and desmin-positivity usual. This and the lack of KIT expression separate leiomyosarcoma from GIST, an important problem in abdominal soft tissues. EBV-associated smooth muscle tumors are a specific subcategory occurring in AIDS or post-transplant patients. These tumors can have incomplete smooth muscle differentiation but show nuclear EBER as a diagnostic feature. In contrast to many other soft tissue tumors, genetics of smooth muscle tumors are poorly understood and such diagnostic testing is not yet generally applicable in this histogenetic group. Leiomyosarcomas are known to be genetically complex, often showing 'chaotic' karyotypes including aneuploidy or polyploidy, and no recurrent tumor-specific translocations have been detected.
authors.affiliation: National Cancer Institute, Laboratory of Pathology, Bethesda, MD, USA.
authors.forename: Markku
authors.initials: M
authors.lastname: Miettinen
mesh_terms: D018229:Angiomyoma / Q000145:classification; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics; D002454:Cell Differentiation; D006222:Hamartoma / Q000145:classification; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D007889:Leiomyoma / Q000145:classification; D007890:Leiomyosarcoma / Q000145:classification; D009379:Neoplasms, Muscle Tissue / Q000737:chemistry / Q000145:classification* / Q000235:genetics / Q000473:pathology / Q000821:virology; D011379:Prognosis; D012983:Soft Tissue Neoplasms / Q000737:chemistry / Q000145:classification* / Q000235:genetics / Q000473:pathology / Q000821:virology; D009626:Terminology as Topic
chemical_list: D014408:Biomarkers, Tumor